FDA Drug Approvals Hit All-Time High In 2018

Bob Carey
Chief Market Strategist

Bio
X • LinkedIn

Blog Home

Send Us Your Comments And Questions

RSS Feed

FDA Drug Approvals Hit All-Time High In 2018

Posted Under: Sectors

View from the Observation Deck

The 59 new drugs approved by the FDA in 2018 eclipsed the previous high of 53 in 1996, according to FierceBiotech.
One of the catalysts behind the jump in approvals the past two years is a more efficient process. Pharma Exec reported that it took 250 days, on average, for a drug using Fast Track status to be approved by the FDA in 2017, down from 300 days in 2015, and the average days for approval in other expedited categories have also decreased, according to StreetAuthority.
The new drug pipeline is deep. In 2018, there were 7,201 Investigational New Drug (IND) applications on the FDA's books, up 25% from a decade ago, according to FierceBiotech. An IND is a request for authorization from the FDA to administer an investigational drug or biological product to humans.
The FDA plans to hire at least 50 new clinical reviewers to assess cell and gene therapies to prepare for a surge in cutting-edge products, according to FierceBiotech.
The need for new products is a primary driver of mergers and acquisitions (M&A) in the biotechnology space, particularly for pharmaceutical companies, according to FierceBiotech. In 2017 alone, more than $26 billion in annual sales was vulnerable due to patent expirations, according to StreetAuthority.
A couple of decades ago, less than 10% of the products in the pharmaceutical pipeline came from biotechnology companies, compared to 65% today, according to Labiotech, a leading digital media firm tracking the European Biotechnology industry. In 2018, 60% of the drugs approved by the FDA came from biotechnology companies.

This chart is for illustrative purposes only and not indicative of any actual investment.

Download a PDF of this post, please click here.

Posted on Tuesday, January 22, 2019 @ 12:15 PM • Post Link

Printer Friendly

These posts were prepared by First Trust Advisors L.P., and reflect the current opinion of the authors. They are based upon sources and data believed to be accurate and reliable. Opinions and forward looking statements expressed are subject to change without notice. This information does not constitute a solicitation or an offer to buy or sell any security.

Most Current Posts

<<< Newer Posts • Older Posts >>>

Search Posts

MARKET ANALYSIS

Market Commentary and Analysis
•	Market Commentary Video
•	Monthly Talking Points
•	Quarterly Newsletter
•	Market Observations

Subscribe To Receive Email

PREVIOUS POSTS
•	A Snapshot of Growth vs. Value Investing
•	S&P 500 Index Earnings & Revenue Growth Rate Projections
•	Corporate Earnings Are Expected To Increase In 2019
•	A Snapshot Of How Stocks Have Performed So Far In This Millennium
•	2019 Market Outlook
•	A Snapshot of Bond Valuations
•	Stock Buybacks by Sector
•	Call Us Crazy ... Stocks on sale as we head into 2019
•	Sector Performance Via Market Capitalization (Since Steel/Aluminum Tariffs Enacted)
•	Top-Performing Subsectors in the S&P 500 Index